Related Experiment Video
Updated: Aug 7, 2026
06:00
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Cyclin E1 knockdown induces apoptosis in cancer cells
Esteban N Gurzov1, Marta Izquierdo
1Departament of Molecular Biology, Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid, Facultad de Ciencias, Cantoblanco, Madrid 28049, Spain.
Neurological Research
|July 1, 2006
Summary
Targeting cyclin E1 (cell cycle regulator) via RNA interference effectively reduced cancer cell growth and induced apoptosis. This approach shows potential for novel cancer therapies by inhibiting tumor development.
Area of Science:
- Molecular Biology
- Cancer Research
- Gene Therapy
Background:
- Cyclin E1 is crucial for cell cycle progression, specifically initiating DNA synthesis.
- Elevated cyclin E1 levels are a common hallmark of various cancer types.
- Understanding cyclin E1's role in cancer is vital for developing targeted therapies.
Purpose of the Study:
- To investigate the impact of reducing cyclin E1 expression in cancer cells.
- To assess the potential of cyclin E1 knockdown as a cancer treatment strategy.
Main Methods:
- Utilized RNA interference delivered via a DNA-based retroviral vector for cyclin E1 knockdown.
- Tested the method across multiple cancer cell lines: adenocarcinoma (HeLa), breast (MDA-MB-31), and glioblastoma (U-373-MG).
- Included a primary glioma patient explant (GB-LP-2) for translational relevance.
Main Results:
- Achieved over 80% depletion of cyclin E1 protein within 96 hours post-infection.
- Induced significant apoptosis in cancer cells, ranging from 50% to 70%.
- Demonstrated complete abolition of tumor growth in nude mice for U-373-MG cells post-knockdown.
Conclusions:
- Retroviral delivery of short hairpin RNA (shRNA) targeting cyclin E1 is highly effective.
- Cyclin E1 knockdown demonstrates potent anti-cancer effects, including apoptosis induction and growth inhibition.
- This shRNA-based approach holds promise as a novel therapeutic agent for cancer treatment.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
01:45Positive Regulator Molecules
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...